Pramlintide acetateProduct ingredient for Pramlintide

Show full entry for Pramlintide
Name
Pramlintide acetate
Drug Entry
Pramlintide

Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.

See full entry for Pramlintide
Accession Number
DBSALT000144
Structure
Similar Structures
Synonyms
Not Available
UNII
726I6TE06G
CAS Number
196078-30-5
Weight
Average: 3951.405
Monoisotopic: 3948.936324209
Chemical Formula
C171H269N51O53S2
InChI Key
NRKVKVQDUCJPIZ-MKAGXXMWSA-N
InChI
InChI=1S/C171H269N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)219-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-121(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)209-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(182)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)215-138(243)83(14)190-157(262)114(73-276)211-168(273)133(87(18)228)216-139(244)84(15)191-164(269)131(85(16)226)217-153(258)108(65-124(179)237)204-158(263)115(74-277)210-140(245)95(173)38-28-29-49-172/h22-27,34-37,43-46,67,75-89,95-118,128-135,223-231,276-277H,21,28-33,38-42,47-66,68-74,172-173H2,1-20H3,(H2,174,232)(H2,175,233)(H2,176,234)(H2,177,235)(H2,178,236)(H2,179,237)(H2,180,238)(H2,181,241)(H,184,188)(H,186,266)(H,187,246)(H,189,249)(H,190,262)(H,191,269)(H,192,239)(H,193,248)(H,194,270)(H,195,271)(H,196,242)(H,197,247)(H,198,250)(H,199,253)(H,200,252)(H,201,254)(H,202,260)(H,203,259)(H,204,263)(H,205,267)(H,206,272)(H,207,268)(H,208,251)(H,209,261)(H,210,245)(H,211,273)(H,212,256)(H,213,255)(H,214,264)(H,215,243)(H,216,244)(H,217,258)(H,218,257)(H,219,265)(H4,182,183,185)/t81-,82-,83-,84-,85+,86+,87+,88+,89+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,128-,129-,130-,131-,132-,133-,134-,135-/m0/s1
IUPAC Name
(2S)-N-[(1S)-4-carbamimidamido-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-2-hydroxy-1-{[(1S)-2-hydroxy-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-({2-[(2S)-2-{[(1S,2S)-1-{[(2S)-1-[(2S)-2-[(2S)-2-{[(1S,2R)-2-hydroxy-1-{[(1S)-1-{[(1S)-1-[({[(1S)-2-hydroxy-1-{[(1S)-1-{[(1S,2R)-2-hydroxy-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-2-(4-hydroxyphenyl)ethyl]-C-hydroxycarbonimidoyl}propyl]-C-hydroxycarbonimidoyl}-2-(C-hydroxycarbonimidoyl)ethyl]-C-hydroxycarbonimidoyl}ethyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-methylpropyl]-C-hydroxycarbonimidoyl}-2-(C-hydroxycarbonimidoyl)ethyl]-C-hydroxycarbonimidoyl}propyl]-C-hydroxycarbonimidoyl}pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]-C-hydroxycarbonimidoyl}-2-methylbutyl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl]-2-oxoethyl}-C-hydroxycarbonimidoyl)-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-(C-hydroxycarbonimidoyl)ethyl]-C-hydroxycarbonimidoyl}-2-(C-hydroxycarbonimidoyl)ethyl]-C-hydroxycarbonimidoyl}ethyl]-C-hydroxycarbonimidoyl}ethyl]-C-hydroxycarbonimidoyl}-2-(1H-imidazol-5-yl)ethyl]-C-hydroxycarbonimidoyl}-2-methylpropyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-(C-hydroxycarbonimidoyl)ethyl]-C-hydroxycarbonimidoyl}ethyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}butyl]-2-{[(2S,3R)-2-{[(2S)-2-{[(2R)-2-{[(2S,3R)-2-{[(2S)-2-{[(2S,3R)-2-{[(2S)-2-{[(2R)-2-{[(2S)-2,6-diamino-1-hydroxyhexylidene]amino}-1-hydroxy-3-sulfanylpropylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene]amino}-1,3-dihydroxybutylidene]amino}-1-hydroxypropylidene]amino}-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-sulfanylpropylidene]amino}-1-hydroxypropylidene]amino}-1,3-dihydroxybutylidene]amino}pentanediimidic acid
SMILES
[H][C@](C)(O)[C@]([H])(N=C(O)[C@]([H])(C)N=C(O)[C@@]([H])(N=C(O)[C@]([H])(CC(O)=N)N=C(O)[C@]([H])(CS)N=C(O)[C@@]([H])(N)CCCCN)[C@@]([H])(C)O)C(O)=N[C@@]([H])(CS)C(O)=N[C@@]([H])(C)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CCC(O)=N)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(C)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CC1=CN=CN1)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=NCC(=O)N1CCC[C@@]1([H])C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CC(C)C)C(=O)N1CCC[C@@]1([H])C(=O)N1CCC[C@@]1([H])C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(C(C)C)C(O)=NCC(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(O)=N)[C@@]([H])(C)O)[C@@]([H])(C)O)[C@@]([H])(C)CC)[C@@]([H])(C)O
PubChem Compound
16132446
ChemSpider
17289104
Wikipedia
Pramlintide
Predicted Properties
PropertyValueSource
logP4.23Chemaxon
pKa (Strongest Acidic)2.31Chemaxon
pKa (Strongest Basic)11.88Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count100Chemaxon
Hydrogen Donor Count66Chemaxon
Polar Surface Area1813.73 Å2Chemaxon
Rotatable Bond Count121Chemaxon
Refractivity1090.21 m3·mol-1Chemaxon
Polarizability409.19 Å3Chemaxon
Number of Rings7Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon